Zcash launches public alpha with zero‑knowledge privacy tech

Zcash published its first public alpha on Wednesday, releasing the source code on GitHub and inviting anyone to try the “preview” network [1]. The alpha runs on a test net that carries no real money, giving the team a chance to hunt bugs before a full launch, which founder Zooko Wilcox estimates is still about six months away [1].

Wilcox, a cryptographer known for the Tahoe LAFS storage system, says Zcash uses zero‑knowledge proofs—specifically zk‑SNARKs—to let senders and receivers keep transaction details hidden while still preventing double‑spending [1]. The design mirrors Bitcoin’s proof‑of‑work mining and 21‑million‑coin cap, but adds optional privacy that Bitcoin’s public ledger lacks [2]. Because the privacy layer is optional, users can choose to disclose transaction data to third parties if regulators require it [2].

The project is structured as a for‑profit company for its first four years, with 10 percent of mined coins earmarked for the startup and 1 percent for a nonprofit that will oversee the code and community [1]. That model is intended to fund development; investors have already contributed more than $715,000, including backers such as Naval Ravikant, Barry Silbert and Roger Ver [1]. Wilcox argues the revenue stream will sustain the effort while keeping the code open‑source.

Regulators, however, remain wary. At least ten countries restrict privacy coins on licensed exchanges, and the EU’s new anti‑money‑laundering rules will ban anonymity‑enhancing tokens like Zcash from regulated venues starting July 2027 [2]. Major exchanges have already delisted privacy coins under pressure, limiting institutional access that Bitcoin enjoys [2]. The optional privacy feature may ease some concerns, but the regulatory headwinds suggest a long road to mainstream adoption.

If Zcash’s privacy tech proves robust and the for‑profit model attracts enough capital, the coin could become a go‑to tool for users needing strong financial confidentiality—from medical startups to individuals in high‑risk regions. Yet the looming regulatory bans raise the question of whether the network can grow enough to survive without institutional support.